臨床検査58巻13号

2014年12月発行

今月の特集1 検査でわかる！M蛋白血症と多発性骨髄腫

多発性骨髄腫の遺伝子検査

著者： 五十嵐哲祥¹ 石田禎夫¹

所属機関： ¹札幌医科大学医学部　消化器・免疫・リウマチ内科学講座

ページ範囲：P.1599 - P.1605

●染色体異数性は染色体数によって，高二倍体（hyperdiploid）と非高二倍体（non-hyperdiploid）に分類される．

●IgH領域での転座の報告では，t（11；14），t（4；14），t（14；16），t（14；20），t（8；14），t（6；14），t（12；14）などが挙げられる．

●t（4；14），17p欠失，1p欠失，1q増幅は予後不良因子と報告されている．

参考文献

1）Kuehl WM, Bergsagel PL：Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer　2：175-187，2002

2）Fonseca R, Bergsagel PL, Drach J, et al：International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia　23：2210-2221，2009

3）Laï JL, Zandecki M, Mary JY, et al：Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood　85：2490-2497，1995

4）Chng WJ, Kumar S, Vanwier S, et al：Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res　67：2982-2989，2007

5）Nishida K, Tamura A, Nakazawa N, et al：The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood　90：526-534，1997

6）Bergsagel PL, Kuehl WM：Chromosome translocations in multiple myeloma. Oncogene　20：5611-5622，2001

7）Chesi M, Bergsagel PL, Brents LA, et al：Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood　88：674-681，1996

8）Zhan F, Huang Y, Colla S, et al：The molecular classification of multiple myeloma. Blood　108：2020-2028，2006

9）Pineda-Roman M, Zangari M, Haessler J, et al：Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol　140：625-634，2008

10）Boyd KD, Ross FM, Chiecchio L, et al：A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia　26：349-355，2012

11）Kapoor P, Fonseca R, Rajkumar SV, et al：Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc　85：532-537，2010

12）Jagannath S, Richardson PG, Sonneveld P, et al：Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia　21：151-157，2007

13）Drach J, Ackermann J, Fritz E, et al：Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood　92：802-809，1998

14）Carrasco DR, Tonon G, Huang Y, et al：High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell　9：313-325，2006

15）Hanamura I, Stewart JP, Huang Y, et al：Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood　108：1724-1732，2006

16）Avet-Loiseau H, Attal M, Campion L, et al：Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol　30：1949-1952，2012

17）Annunziata CM, Davis RE, Demchenko Y, et al：Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell　12：115-130，2007

18）Chng WJ, Gonzalez-Paz N, Price-Troska T, et al：Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia　22：2280-2284，2008

19）Avet-Loiseau H, Attal M, Moreau P, et al：Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood　109：3489-3495，2007

20）Moreau P, Cavo M, Sonneveld P, et al：Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. J Clin Oncol　32：2173-2180，2014

21）Shaughnessy JD Jr, Zhan F, Burington BE, et al：A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood　109：2276-2284，2007